Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,147
- Phase 21,063
- Phase 1819
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis140
- Type 1 Diabetes133
- Atopic Dermatitis129
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California491
- Maryland195
- Alabama175
- Florida144
- Arizona142
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT07116070Recruiting
Sarcopenia and muscle loss in multiple sclerosis patients
This study looks at muscle loss (sarcopenia) in people with multiple sclerosis. It aims to understand what factors are linked to muscle loss, which could help improve care.
Konya, SelcukluAges 18 years+ - NCT07116460Recruiting
Air filters for asthma in low-income housing
This study tests whether air filters placed in homes can reduce asthma symptoms in children and teens living in low-income housing in Northern Manhattan and the South Bronx. If you have asthma and are between 7 and 18 years old, you may be able to join.
New York, New YorkAges 7–18 - NCT07116434Recruiting
Discovery diabetes support for teens and young adults
This study uses a smartphone app and digital stories to help teens and young adults with type 1 diabetes learn more about managing their condition and connect with others. You may join if you have had type 1 diabetes for at least a year, have a smartphone, and have an upcoming clinic visit at Vanderbilt.
Nashville, TennesseeAges 13–21 - NCT07116616RecruitingPhase 1/Phase 2
mRNA vaccine for relapsed or refractory multiple myeloma
This trial tests an experimental mRNA therapy called mRNA-2808 for people with multiple myeloma that has returned or stopped responding to prior treatments. It aims to see if it can help control the disease.
Birmingham, AlabamaAges 18 years+ - NCT07117669RecruitingPhase 1/Phase 2
Testing a new peanut allergy treatment (ENP-501)
This trial tests a new peanut allergy treatment called ENP-501. It aims to see if the medicine can safely help people with peanut allergy become less sensitive to peanuts.
Aurora, ColoradoAges 14–50 - NCT07117981Recruiting
Study of second-line treatment for thyroid eye disease
This trial looks at how thyroid eye disease (inflammation behind the eyes) changes over time in people who need stronger treatments after steroids haven't worked well enough. It aims to better understand the disease and how different second-line treatments may help.
Paris, parisAges 18 years+ - NCT07118241RecruitingPhase 2
Testing a new eye drop for Sjögren's dry eye
This trial tests a new eye drop made from a natural protein (rhPRG4) to see if it safely and effectively relieves dry eye symptoms in people with Sjögren's syndrome. You'll be randomly assigned to receive the study drop or a placebo (inactive) drop for several weeks.
Sydney, New South WalesAges 18–80 - NCT07118254RecruitingPhase 2
Eye drops for dry eye from graft-versus-host disease
This study tests whether a new eye drop (rhPRG4) can safely reduce dry eye symptoms caused by graft-versus-host disease (GVHD). It compares the active drops to an inactive placebo to see if they provide better relief.
Sydney, New South WalesAges 18–75 - NCT07118657Recruiting
Vegan diet's effect on gut health in kids with autoimmune hepatitis
This study looks at how a vegan diet changes the bacteria in the gut and how that affects diet and disease in children with autoimmune hepatitis. Healthy children are included as a comparison group.
New Delhi, National Capital Territory of DelhiAges birth–18 years - NCT07118683Recruiting
Brazilian health study for people with HIV or AIDS
This study is creating a record of chronic health conditions (like heart disease, diabetes, or high blood pressure) in people living with HIV or AIDS in Brazil. Joining helps researchers better understand and care for the health needs of people like you.
Goiânia, GoiásAges 18 years+ - NCT07119359Recruiting
TB and HIV prevention study for households in Uganda
This study tests whether adding HIV prevention services to routine TB household contact checks can help more people stay healthy. If you or someone you live with has TB, you may be able to join.
KampalaAges 15 years+ - NCT07121777Recruiting
CAR T cell therapy for autoimmune diseases
This study tests a new type of cell therapy (CAR T cells) that targets certain immune cells to treat autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, and systemic sclerosis. It may help people whose disease is not well controlled with standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07122076RecruitingEarly Phase 1
GT719 injection for moderate to severe autoimmune diseases
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
ShanghaiAges 18–65 - NCT07123038Recruiting
Long-term safety study for gene-modified Treg therapy recipients
This study follows people who previously received a gene-modified Treg (regulatory T cell) therapy from Sonoma Biotherapeutics. It checks for long-term safety and does not involve any new treatment.
San Francisco, CaliforniaAges 18–71 - NCT07123519RecruitingPhase 1
YTS109 cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
TianjinAges 18–65 - NCT07123909Recruiting
Immune adsorbent therapy for dialysis patients with inflammation
This study tests a therapy that absorbs inflammatory substances from the blood during dialysis. It may help people on dialysis who have ongoing inflammation, shown by high IL-6 or CRP levels.
MoscowAges 18 years+ - NCT07124572Recruiting
Building a Better Diagnosis System for Thyroid Eye Disease
This study aims to build a better system for diagnosing and treating thyroid-associated ophthalmopathy (a thyroid eye condition). It may help improve care for people with this disease, and also involves healthy volunteers as a comparison group.
Hangzhou, ZhejiangAges 7–90 - NCT07124936RecruitingPhase 1/Phase 2
Study of new drug plus standard care for large B-cell lymphoma
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07125365Recruiting
UK study tracking islet antibodies in children and adults
This study enrolls people with islet autoantibodies, which are early markers for type 1 diabetes. It aims to understand who develops these antibodies and how they are linked to diabetes over time. No treatment is given—you just provide blood samples and answer questions.
Oxford, OxfordshireAges 6 months–70 years - NCT07125872RecruitingPhase 2
New drug for relapsed B-cell lymphoma
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
JohannesburgAges 18 years+ - NCT07126236RecruitingPhase 2
Epcoritamab for first relapse of large B-cell lymphoma
This trial tests a new drug called epcoritamab for people whose large B-cell lymphoma has come back after or didn't fully respond to their first treatment. It's an option for those who cannot or choose not to have CAR-T therapy or a stem cell transplant.
Zaragoza, AragonAges 18 years+ - NCT07126431Recruiting
Study of hard-to-treat rheumatoid arthritis
This study is observing people with a hard-to-treat form of rheumatoid arthritis (RA). Researchers want to understand what treatments and outcomes are like for people whose RA doesn't get better with standard medications like methotrexate.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07126678Recruiting
Zanubrutinib, Bendamustine, and Obinutuzumab for advanced follicular lymphoma
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT07126873RecruitingPhase 1/Phase 2
Study of E-islet 01 for type 1 diabetes with severe low blood sugar
This study tests a new treatment called E-islet 01, which may help people with type 1 diabetes who have very low natural insulin production and have had dangerous low blood sugar events. The goal is to see if it is safe and can reduce those episodes.
Shanghai, Shanghai MunicipalityAges 18–75
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,763 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.